{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-019363","form_type":"8-K","ticker":"CYDY","cik":"0001175680","company_name":"CytoDyn Inc.","filed_at":"2023-11-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.421062+00:00","generated_at":"2026-06-07T20:48:17.846569+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Samsung BioLogics terminates MSA with CytoDyn effective Jan 5, 2024; company has sufficient leronlimab for trials","bullets":["Samsung informed CytoDyn on Nov 21, 2023 of intent to terminate MSA effective Jan 5, 2024.","Agreement from April 2019 covered tech transfer, manufacturing, vial filling, and supply for leronlimab.","Samsung paused manufacturing for all unfulfilled commitments in January 2022.","CytoDyn states it holds sufficient leronlimab for short-term prospective clinical trials.","Company plans to continue resolving outstanding issues including breach notice, payment schedule, and extended manufacturing postponement."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-019363","json":"https://secwatch.observer/filing/0001558370-23-019363.json","markdown":"https://secwatch.observer/filing/0001558370-23-019363.md","text":"https://secwatch.observer/filing/0001558370-23-019363.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1175680/000155837023019363/0001558370-23-019363-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1175680/000155837023019363/cydy-20231121x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T20:48:17.846569+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"911c0ef7053dde347590e90eb9d37192a23c0c94","claim":"CytoDyn Inc. terminated Master Services Agreement with Samsung BioLogics Co., Ltd. (effective 2023-11-21).","evidence_excerpt":"On November 21, 2023, Samsung BioLogics Co., Ltd. (“Samsung”), informed CytoDyn Inc., a Delaware corporation (the “Company”), of Samsung’s intent to terminate, effective January 5, 2024, the Master Services Agreement (the “Agreement”) entered into between Samsung and the Company in April 2019.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1175680/000155837023019363/0001558370-23-019363-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"Samsung BioLogics Co., Ltd."},{"label":"Effective","value":"2023-11-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}